Meeting to be held in Boston on April 8 and in New York on April 9 hosted by Piper Sandler.Stay Ahead of the Market: Discover outperforming ...

Sto plans to reduce dividend distribution to shareholders: basic dividend remains at previous year's level, bonus to be reduced ...

The fear of a trade war over pharmaceuticals between the EU and the US has been avoided for now, but the European Commission remains on guard, considering further tariff deployments likely.

It demands significant resources that are often expensive and inaccessible to biotechnology and pharmaceutical companies of all sizes. Federal regulations like the Current Good Manufacturing ...

Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of $355 million, or $4.10 per share, the companies said Sunday. With Unloxcyt, an FDA-approved PD-L1 therapy for ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China. According to data from DealForma ...

Governments and employers worldwide have expanded access to care. Yet pharmaceutical innovation hasn’t kept pace. Since the blockbuster success of drugs such as Prozac and Zoloft in the 1990s ...

President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result in shortages and higher prices for generic drugs. By Rebecca Robbins ...

MLB, Topps and Nike have partnered to recognize baseball's elite performers from last season with custom gold-embellished MLB logos on their jerseys that will then be used to create trading cards.

From Government Buildings to the corridors of the European Parliament – and even a playground in Bray, Co Wicklow – the pharmaceutical industry has been quietly waging a massive lobbying campaign.

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing ...